English
Theralizumab Biosimilar - Research Grade
Theralizumab Biosimilar - Research Grade, Human IgG4
Artikelnummer
ICH5023-1MG
Verpackungseinheit
1mg
Hersteller
Ichorbio
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Target: CD28.
Specificity: Detects human CD28. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Theralizumab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background: Theralizumab GN1412 is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system’s T cells. CD28 is the co-receptor for the T cell receptor; It binds to receptors on the interacting partner in the reaction through one of its ligands (B7 family). It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by PAREXEL in London in March 2006.
Concentration: 5mg/ml.
Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Purity: >95% by SDS-PAGE.
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Specificity: Detects human CD28. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Theralizumab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background: Theralizumab GN1412 is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system’s T cells. CD28 is the co-receptor for the T cell receptor; It binds to receptors on the interacting partner in the reaction through one of its ligands (B7 family). It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by PAREXEL in London in March 2006.
Concentration: 5mg/ml.
Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Purity: >95% by SDS-PAGE.
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
